Cargando…

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination

Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low...

Descripción completa

Detalles Bibliográficos
Autor principal:	Filippatos, Theodosios D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368211/ https://www.ncbi.nlm.nih.gov/pubmed/22592524 http://dx.doi.org/10.1007/s10557-012-6394-0

Ejemplares similares

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes
por: Shinnakasu, Atsushi, et al.
Publicado: (2017)

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2010)

Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review
por: Tziomalos, Konstantinos, et al.
Publicado: (2006)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
por: Reyes-Soffer, Gissette, et al.
Publicado: (2013)

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides
por: Ballantyne, Christie M., et al.
Publicado: (2011)

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
por: Bays, Harold E., et al.
Publicado: (2010)

Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study
por: Das, Mithun, et al.
Publicado: (2015)

Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
por: Kim, Nam Hoon, et al.
Publicado: (2019)

Thiazide–associated hyponatremia in the elderly: what the clinician needs to know
por: Liamis, George, et al.
Publicado: (2016)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas
por: Zhu, Wei, et al.
Publicado: (2021)

Preparation and Evaluation of Lipid-Based Liquid Crystalline Formulation of Fenofibrate
por: Kazemi, Moloud, et al.
Publicado: (2018)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
por: Christopoulou, Eliza, et al.
Publicado: (2019)

Hyponatremia in the elderly: challenges and solutions
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate
por: Aslibekyan, Stella, et al.
Publicado: (2012)

Fenofibrate-induced renal dysfunction, yes or no?
por: Emami, Fatemeh, et al.
Publicado: (2020)

Effect of fenofibrate on uric acid level in patients with gout
por: Jung, Ju-Yang, et al.
Publicado: (2018)

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
por: van Stee, Mariël F., et al.
Publicado: (2018)

Anticancer Properties of Fenofibrate: A Repurposing Use
por: Lian, Xin, et al.
Publicado: (2018)

Anti-inflammatory role of fenofibrate in treating diseases
por: Jin, Lv, et al.
Publicado: (2023)

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study
por: Kwon, Taek-Geun, et al.
Publicado: (2020)

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
por: Zhang, Yan, et al.
Publicado: (2015)

Integrative methylation score to identify epigenetic modifications associated with lipid changes resulting from fenofibrate treatment in families
por: Wang, Biqi, et al.
Publicado: (2018)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Effect and safety of combination lipid‐lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events
por: Wang, Chunli, et al.
Publicado: (2018)

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
por: Benes, Lane B, et al.
Publicado: (2016)

Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
por: Castaldo, Richard S.
Publicado: (2016)

Fibrane the reduced derivative of fenofibrate
por: Kotheimer, Amanda E., et al.
Publicado: (2019)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics
por: Alamri, Rayan G., et al.
Publicado: (2017)

A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019
por: Chirinos, Julio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mklag9i8shgsqsa10nofom83dh